|
KALV | Kalvista Pharmaceuticals, Inc. |
|
|
KALV | Kalvista Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.54 |
| Leverage | 13.69% |
| Market Cap | $ 321.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -140.3m |
| Margin | -1583.32% |
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.